{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:51:43Z","timestamp":1793893903625,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8110","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.1038\/s41586-026-10244-w","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:06:04Z","timestamp":1773245164000},"page":"731-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"652","author":[{"given":"Jiawei","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Xue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Lu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-1473","authenticated-orcid":false,"given":"Melvin. L. K.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-4989","authenticated-orcid":false,"given":"Zi-Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-1454","authenticated-orcid":false,"given":"Ling-Long","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-071X","authenticated-orcid":false,"given":"Yan-Ping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-5524","authenticated-orcid":false,"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8590-875X","authenticated-orcid":false,"given":"Zhi-Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Sheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ye","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-3888","authenticated-orcid":false,"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Bin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sheng","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Hua","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0769","authenticated-orcid":false,"given":"Jing-Ping","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-4224","authenticated-orcid":false,"given":"Guan-Qun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-9349","authenticated-orcid":false,"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-2929","authenticated-orcid":false,"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"10244_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic\u2014implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297\u2013312 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10244_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124\u20131135 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10244_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv, J. et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell 42, 1401\u20131414 (2024).","journal-title":"Cancer Cell"},{"key":"10244_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","volume":"178","author":"DM Kurtz","year":"2019","unstructured":"Kurtz, D. M. et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 178, 699\u2013713 (2019).","journal-title":"Cell"},{"key":"10244_CR5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29, 1424\u20131436 (2023).","journal-title":"Nat. Med."},{"key":"10244_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621, 868\u2013876 (2023).","journal-title":"Nature"},{"key":"10244_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259\u2013268 (2023).","journal-title":"Nature"},{"key":"10244_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363\u2013376 (2020).","journal-title":"Cell"},{"key":"10244_CR9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 41, 1763\u20131773 (2023).","journal-title":"Cancer Cell"},{"key":"10244_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv, J. et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat. Commun. 10, 3941 (2019).","journal-title":"Nat. Commun."},{"key":"10244_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02463-5","volume":"20","author":"J Lv","year":"2022","unstructured":"Lv, J. et al. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med 20, 268 (2022).","journal-title":"BMC Med"},{"key":"10244_CR12","unstructured":"Brierley, J. D. et al. (eds) TNM Classification of Malignant Tumours 8th edn (Wiley-Blackwell, 2016)."},{"key":"10244_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12347","volume":"42","author":"YP Chen","year":"2022","unstructured":"Chen, Y. P. et al. Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma. Cancer Commun. 42, 909\u2013912 (2022).","journal-title":"Cancer Commun."},{"key":"10244_CR14","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 403, 2720\u20132731 (2024).","journal-title":"Lancet"},{"key":"10244_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"Y-L Liang","year":"2025","unstructured":"Liang, Y.-L. et al. Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial. J. Am. Med. Assoc. 333, 1589\u20131598 (2025).","journal-title":"J. Am. Med. Assoc."},{"key":"10244_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong, S. et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 10, 932\u2013940 (2024).","journal-title":"JAMA Oncol."},{"key":"10244_CR17","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10244_CR18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"10244_CR19","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"10244_CR20","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat. Med. 31, 4291\u20134300 (2025).","journal-title":"Nat. Med."},{"key":"10244_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijrobp.2025.09.044","volume":"124","author":"L Chen","year":"2026","unstructured":"Chen, L. et al. Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH study). Int. J. Radiat. Oncol. Biol. Phys. 124, 676\u2013685 (2026).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10244_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijrobp.2025.03.076","volume":"123","author":"Z Huang","year":"2025","unstructured":"Huang, Z. et al. Plasma Epstein\u2013Barr virus DNA temporal clearance pattern during induction-concurrent (chemo)radiation therapy for risk stratification in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 123, 129\u2013140 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10244_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen, Y. P. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398, 303\u2013313 (2021).","journal-title":"Lancet"},{"key":"10244_CR24","doi-asserted-by":"crossref","unstructured":"Tang, L.-L. et al. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma. Holist. Integr. Oncol. 2, 24, (2023).","DOI":"10.1007\/s44178-023-00040-1"},{"key":"10244_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(24)00504-7","volume":"25","author":"SL Liu","year":"2024","unstructured":"Liu, S. L. et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 25, 1563\u20131575 (2024).","journal-title":"Lancet Oncol."},{"key":"10244_CR26","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497\u20131508 (2016).","journal-title":"Lancet Oncol."},{"key":"10244_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"10244_CR28","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le, Q. T. et al. An international collaboration to harmonize the quantitative plasma Epstein\u2013Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin. Cancer Res. 19, 2208\u20132215 (2013).","journal-title":"Clin. Cancer Res."},{"key":"10244_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.radonc.2021.12.029","volume":"167","author":"SQ Tang","year":"2022","unstructured":"Tang, S. Q. et al. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother. Oncol. 167, 179\u2013186 (2022).","journal-title":"Radiother. Oncol."},{"key":"10244_CR30","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin, J. C. et al. Quantification of plasma Epstein\u2013Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350, 2461\u20132470 (2004).","journal-title":"N. Engl. J. Med."},{"key":"10244_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan, K. C. A. et al. Analysis of plasma Epstein\u2013Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513\u2013522 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10244_CR32","first-page":"1188","volume":"59","author":"YM Lo","year":"1999","unstructured":"Lo, Y. M. et al. Quantitative analysis of cell-free Epstein\u2013Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59, 1188\u20131191 (1999).","journal-title":"Cancer Res."},{"key":"10244_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/sim.6394","volume":"34","author":"R Schmidt","year":"2015","unstructured":"Schmidt, R. et al. Sample size calculation for the one-sample log-rank test. Stat. Med. 34, 1031\u20131040 (2015).","journal-title":"Stat. Med."},{"key":"10244_CR34","first-page":"35","volume":"17","author":"\u00d8 Borgan","year":"1990","unstructured":"Borgan, \u00d8 & Liest\u00f8l, K. A note on confidence intervals and bands for the survival function based on transformations. Scand. J. Stat. 17, 35\u201341 (1990).","journal-title":"Scand. J. Stat."},{"key":"10244_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","volume":"39","author":"DA Schoenfeld","year":"1983","unstructured":"Schoenfeld, D. A. Sample-size formula for the proportional-hazards regression model. Biometrics 39, 499\u2013503 (1983).","journal-title":"Biometrics"},{"key":"10244_CR36","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41592-024-02405-4","volume":"21","author":"CF Kurz","year":"2024","unstructured":"Kurz, C. F., Krzywinski, M. & Altman, N. Propensity score matching. Nat. Methods 21, 1770\u20131772 (2024).","journal-title":"Nat. Methods"},{"key":"10244_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139\u2013144 (1998).","journal-title":"J. Clin. Oncol."},{"key":"10244_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram, M. Y. et al. Cost-effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925\u2013930 (2016).","journal-title":"Bull. World Health Organ."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10244-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:09:08Z","timestamp":1778076548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10244-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":38,"journal-issue":{"issue":"8110","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10244"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10244-w","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.K.C. reports personal fees for advisory board and education activities and funding support from BeiGene (tislelizumab) for an investigator-initiated trial; personal fees from TopAlliance Biosciences (toripalimab) for advisory board activities; personal fees from Astellas, Pfizer, MSD, AstraZeneca, Varian, Janssen, IQVIA and Telix Pharmaceuticals; nonfinancial support from AstraZeneca; nonfinancial support from Veracyte; and personal fees and grants from Bayer. M.L.K.C. consults for ImmunoSCAPE; is a co-inventor on the patent \u2018High sensitivity lateral flow immunoassay for detection of analyte in sample\u2019 (10202107837T, Singapore); and serves on the board of directors of Digital Life Line, which owns the licensing agreement of the patent. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}